NEWS: Amber Implants Secures FDA 510(k) Clearance for VCFix® Spinal System: A Next-Generation Solution for Vertebral Compression Fractures

/in

FDA clearance confirms robust safety and performance of VCFix® Spinal System, a breakthrough treatment for vertebral compression fractures US commercial pilot launch planned for early 2026, followed by broader physician availability from summer 2026 One-year trial data show significant clinical improvements, supporting VCFix® Spinal System as a potential new standard of care The Hague, The […]

Read more

Resolution Therapeutics appoints Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer

/in

Highly experienced Chief Financial Officer set to drive corporate and strategic goals of Resolution. Accomplished Chief Business Officer will drive business development and partnering deals. Appointments follow the announcement of the first patient dosed and safety cleared in its Phase I/II EMERALD study. Edinburgh and London, UK 10 September 2025 – Resolution Therapeutics (“Resolution” or “Company”), a clinical-stage biopharmaceutical […]

Read more

Kling Bio Validates its Proprietary B-Cell Technology for Rapid Response Against Emerging Viral Variants

/in

Study demonstrated the use of immortalized B-cell libraries as a rapid and adaptable approach to therapeutic development against evolving viral threats Discovered 12 antibodies with potent neutralizing activity against multiple SARS-CoV-2 strains, including Delta and BA.5, through high-throughput B-cell screening Applied ex vivo directed evolution to B-cell clones to enhance antibody neutralizing breadth and potency […]

Read more

Results from BIG D-FOOT study using STIMULAN® when treating DFO to be presented at EBJIS 2025

/in

Randomised, double-blinded, controlled BIG D-FOOT study demonstrates that local antibiotic delivery using STIMULAN® significantly reduces post-surgical infective complications in patients with diabetic foot osteomyelitis (DFO) Biocomposites symposium will explore best practice treatment strategies for complex infections and share findings from the BIG D FOOT study Keele, UK, 9 September 2025 – Biocomposites, an international medical […]

Read more

DeuterOncology to Present Promising Phase I DO-2 MET Kinase Inhibitor Data at WCLC 2025

/in

DO-2 is a best-in-class MET kinase inhibitor that has completed enrollment in a Phase 1 dose escalation study Tumor shrinkage was observed in 100% of MET exon 14 skip NSCLC patients without additional oncogenic drivers, at doses that achieved preclinically defined thresholds DO-2 has a very good safety profile with minimal peripheral oedema and clean […]

Read more